"Angiogenesis Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents and endogenous substances that antagonize or inhibit the development of new blood vessels.
| Descriptor ID |
D020533
|
| MeSH Number(s) |
D27.505.696.377.077.099 D27.505.696.377.450.100 D27.505.954.248.025
|
| Concept/Terms |
Angiogenesis Inhibitors- Angiogenesis Inhibitors
- Neovascularization Inhibitors
- Angiogenic Antagonists
- Angiogenic Inhibitors
- Angiostatic Agents
- Agents, Angiostatic
- Antagonists, Angiogenic
- Anti-Angiogenetic Agents
- Agents, Anti-Angiogenetic
- Anti Angiogenetic Agents
- Anti-Angiogenic Drugs
- Anti Angiogenic Drugs
- Drugs, Anti-Angiogenic
- Antiangiogenic Agents
- Agents, Antiangiogenic
- Inhibitors, Angiogenesis
- Inhibitors, Angiogenetic
- Inhibitors, Angiogenic
- Inhibitors, Neovascularization
- Angiogenetic Antagonists
- Antagonists, Angiogenetic
- Angiogenetic Inhibitors
Anti-Angiogenesis Effect- Anti-Angiogenesis Effect
- Anti Angiogenesis Effect
- Effect, Anti-Angiogenesis
- Antiangiogenesis Effect
- Effect, Antiangiogenesis
- Antiangiogenesis Effects
- Effects, Antiangiogenesis
- Anti-Angiogenesis Effects
- Anti Angiogenesis Effects
- Effects, Anti-Angiogenesis
|
Below are MeSH descriptors whose meaning is more general than "Angiogenesis Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Angiogenesis Inhibitors".
This graph shows the total number of publications written about "Angiogenesis Inhibitors" by people in this website by year, and whether "Angiogenesis Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 6 | 1 | 7 |
| 2003 | 3 | 2 | 5 |
| 2004 | 3 | 3 | 6 |
| 2005 | 2 | 2 | 4 |
| 2006 | 7 | 1 | 8 |
| 2007 | 15 | 1 | 16 |
| 2008 | 7 | 2 | 9 |
| 2009 | 9 | 5 | 14 |
| 2010 | 10 | 2 | 12 |
| 2011 | 10 | 1 | 11 |
| 2012 | 9 | 5 | 14 |
| 2013 | 17 | 3 | 20 |
| 2014 | 7 | 11 | 18 |
| 2015 | 20 | 6 | 26 |
| 2016 | 8 | 6 | 14 |
| 2017 | 5 | 2 | 7 |
| 2018 | 10 | 8 | 18 |
| 2019 | 10 | 13 | 23 |
| 2020 | 7 | 12 | 19 |
| 2021 | 6 | 14 | 20 |
| 2022 | 1 | 10 | 11 |
| 2023 | 0 | 1 | 1 |
| 2024 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Angiogenesis Inhibitors" by people in Profiles.
-
Quintanilha JCF, Kelly WK, Innocenti F. Contribution of plasma levels of VEGF-A and angiopoietin-2 in addition to a genetic variant in KCNAB1 to predict the risk of bevacizumab-induced hypertension. Pharmacogenomics J. 2024 Jul 12; 24(4):22.
-
Cullhed Farrell A, Epstein D. RETINAL VEIN OCCLUSIONS BEFORE AND DURING THE COVID-19 PANDEMIC: Visual Outcomes and Treatment Patterns in a Country with no Mandatory Lockdown. Retina. 2024 Jun 01; 44(6):1045-1051.
-
Weng CY, Singh RP, Gillies MC, Regillo CD. Optimizing Visual Outcomes in Patients With Neovascular Age-Related Macular Degeneration: the Potential Value of Sustained Anti-VEGF Therapy. Ophthalmic Surg Lasers Imaging Retina. 2023 Nov; 54(11):654-659.
-
Patel SN. Pulmonary Hypertension and Anti-Vascular Endothelial Growth Factor Therapy for Retinopathy of Prematurity-Is There a Link? JAMA Ophthalmol. 2022 11 01; 140(11):1094-1095.
-
Salabati M, Mahmoudzadeh R, Starr MR, Zhang Q, Sharpe J, Hsu J, Ho AC, Regillo C, Kuriyan AE. REFRACTIVE ERROR CHANGE DURING TREATMENT OF DIABETIC MACULAR EDEMA: A Post Hoc Analysis of the Diabetic Retinopathy Clinical Research Protocol T Trial. Retina. 2022 11 01; 42(11):2059-2065.
-
Samuelson AG, Nahar A, Patel SN, Mahmoudzadeh R, Salabati M, Yu-Chuan Kang E, Hinkle JW, Soares RR, Kuriyan AE, Garg SJ. CLINICAL OUTCOMES OF PATIENTS WITH ENDOPHTHALMITIS AFTER DEXAMETHASONE INTRAVITREAL IMPLANT. Retina. 2022 10 01; 42(10):1915-1920.
-
Shah SM, Boopathiraj N, Starr MR, Dalvin LA, AbouChehade J, Damento G, Garcia MD, Hodge DO, Bakri SJ, Sit AJ, Iezzi R. Risk, Prevalence, and Progression of Glaucoma in Eyes With Age-Related Macular Degeneration Treated With Intravitreal Anti-Vascular Endothelial Growth Factor Injections. Am J Ophthalmol. 2022 11; 243:98-108.
-
Patel SN, Mokhashi N, Peck TJ, Cai LZ, Salabati M, Soares RR, Hinkle J, Chaudhary V, Kuriyan AE, Cohen MN, Hsu J, Garg SJ. Seasonal and Environmental Variations in Endophthalmitis after Intravitreal Anti-vascular Endothelial Growth Factor Injection: A Six-year Review. Curr Eye Res. 2022 09; 47(9):1288-1293.
-
Wakabayashi T, Yonekawa Y. Surgical Complications in Retinopathy of Prematurity: Literature Review and Management Strategies. Int Ophthalmol Clin. 2022 07 01; 62(3):3-14.
-
Sharma A, Parachuri N, Kumar N, Kuppermann BD, Bandello F, Regillo CD. The port delivery system with ranibizumab: understanding nuances for clinical use in the real world. Expert Opin Biol Ther. 2022 06; 22(6):675-677.